#LCSM chat 8/13 8pm ET: How can we fight the rising cost of cancer care?
Q A July 23 article in Newsweek titled “The High Cost of Cancer Care: Your Money or Your Life?” emphasizes a topic of increasing concern: the escalating costs of new cancer drugs, and the toll this takes on patients and families. A presentation at ASCO 2015 titled “Perspectives in Value” graphically showed the escalating price of cancer drugs in recent years, and how those prices soar off the charts for some new immunotherapies. The presentation also showed how prices of targeted therapy drugs don’t seem to go down as more patients use… Read More
#LCSM Chat Topic 3/26: The Landscape of the #LungCancer World After Opdivo–Where We Are, Where We’re Going
Post by #LCSM Moderator Dr. H. Jack West: Earlier this month, the FDA made quick work of the application that Bristol-Myers-Squibb had just completed for Opdivo (nivolumab) for patients with squamous cell NSCLC that has previously been treated with standard chemotherapy. This was a very rapid decision, which highlighted the improvement in median overall survival from 6 to 9.2 months. So where are we now? What are the implications of the approval, both in terms of future approvals and the current treatment options for patients? Will Opdivo be the default best treatment… Read More
#LCSM Chat Topic 1/15 at 8PM ET: “Should the FDA Regulate Which Cancer Tests You Can Have?”
The US Food and Drug Administration (FDA) announced its intention to regulate laboratory developed tests. Under the FDA’s proposed Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs) — which treats LDTs as medical devices and healthcare providers as manufacturers — laboratories would have to submit applications for expensive premarket review for thousands of LDTs if they wish to continue offering them to patients. This could limit access to life-saving genomic testing for patients who have cancer and other conditions treatable with targeted drugs. This Thursday, January 15, 2015, at 8 PM… Read More
#LCSM 
You must be logged in to post a comment.